CAPR stock forecast, quote, news & analysis

Key Takeaways

• Capricor Therapeutics (CAPR) is a clinical-stage biotech whose near-term outlook is dominated by the U.S. FDA review of its lead candidate, Deramiocel, for Duchenne muscular dystrophy (DMD).
• Over roughly the past 30 days, the stock has traded in a range without a sustained double-digit move, reflecting a balance between recent analyst upgrades and lingering regulatory and legal uncertainty.
• The FDA extended the review timeline for Deramiocel to November 22, 2026, which several analysts framed as a window for additional data or regulatory clarity.
• Analyst sentiment has turned more constructive, with upgrades from Piper Sandler, B. Riley, and Oppenheimer despite the stock's sharp decline in July 2026.
• Outstanding securities class actions tied to the HOPE-3 trial's statistical analysis plan remain a key overhang on investor sentiment.

Current Market Snapshot

Capricor Therapeutics has remained in the single digits as the market weighs competing signals around its lead asset. Following a steep selloff in late July 2026, the stock stabilized and has since traded largely sideways, with day-to-day moves driven by analyst actions and regulatory headlines rather than a single directional catalyst. The shares have shown meaningful volatility over the past year, and their current level sits well below the 52-week high reached before FDA briefing documents raised questions about the HOPE-3 trial analysis. With limited commercial revenue to date, valuation continues to hinge on expectations for future Deramiocel approval and commercialization rather than current financial results.

Capricor Therapeutics (CAPR) Business Overview and Competitive Position

Capricor Therapeutics is a San Diego-based biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical need. Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiosphere-derived cell (CDC) therapy being developed for the treatment of Duchenne muscular dystrophy. The clinical program has focused primarily on adolescents and young adults with DMD, including many non-ambulatory patients experiencing progressive cardiac and skeletal muscle decline. The company is also advancing a StealthX exosome platform designed for vaccine and therapeutic applications. As a clinical-stage developer without meaningful product sales, Capricor is evaluated primarily on clinical data, regulatory progress, and its cash runway rather than conventional earnings metrics.

Recent Developments Driving CAPR

Regulatory news has been the central driver of Capricor's share price. In late July 2026, the release of FDA briefing documents ahead of an advisory committee meeting triggered a sharp single-session decline, as the agency characterized certain analyses of the Phase 3 HOPE-3 trial as post-hoc and exploratory and an advisory committee voted against efficacy support. The stock has since been working through the consequences of that disclosure.

In September 2026, sentiment shifted as the FDA extended the action date for the Deramiocel biologics license application to November 22, 2026. Analysts interpreted the extension as a potential opportunity for the company to submit additional data or secure further regulatory clarity. Piper Sandler upgraded the stock to Overweight with a price target of $25, B. Riley moved to Buy with a $21 target, and Oppenheimer raised its view to Outperform with a $54 target. These upgrades reflected a more optimistic read on the risk-reward profile heading into the extended review period.

Offsetting that optimism, several law firms announced securities class actions alleging that the company did not follow the pre-specified blinding and protocol procedures for HOPE-3 and that investors were not informed of deviations between the final statistical analysis plan and the trial protocol. This litigation remains an ongoing source of uncertainty.

Trending AI Robots

Investors tracking momentum and volatility in clinical-stage biotechnology names can also monitor automated strategies through Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are surfaced in this curated section. The bots vary in strategy, timeframe, and performance metrics, giving users a way to explore algorithm-driven approaches alongside their own research. For those interested in how AI tools evaluate stocks like Capricor, the page provides a practical starting point for reviewing currently highlighted systems.

2026 Outlook and What Investors Should Watch

The defining event for Capricor in 2026 is the FDA's decision on Deramiocel, now expected on November 22, 2026. The outcome will determine whether the company can transition from a clinical-stage developer toward a commercial-stage cell therapy provider, and it will materially reshape the investment thesis in either direction.

Beyond the regulatory decision, investors should monitor several factors. Any additional data submissions or communications with the FDA ahead of the action date could influence sentiment. The company's cash position, reported at roughly $237.9 million as of June 30, 2026, provides runway but remains a key metric as research and development and general and administrative expenses continue to rise. The progress of the StealthX exosome platform and any international regulatory or partnership activity for Deramiocel also carry longer-term relevance. Finally, the outcome of the securities class actions and analyst target revisions could continue to drive short-term volatility. As with all clinical-stage biotechnology investments, the potential for a binary regulatory outcome means the risk profile is elevated.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations